Quantcast

Neurosurgery journal published study reinforces value of high-field iMRI

April 17, 2014

VISIUS intraoperative MRI significantly enhances amount of complete
resection in brain tumors and leads to better patient outcomes

MINNEAPOLIS, April 17, 2014 /PRNewswire/ – IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
(“IMRIS” or the “Company”) today announced that a study published this
month in the journal Neurosurgery by the neurosurgical team at Cleveland Clinic adds to growing clinical
evidence which validates use of high-field intraoperative MRI (iMRI) as
an effective tool for maximizing the amount of surgical resection of
gliomas (brain tumors).

Conducted using an IMRIS VISIUS(®) Surgical Theatre, the study retrospectively reviewed use of high-field
1.5T (tesla) iMRI on the extent of resection of enhancing (high-grade)
and non-enhancing (low-grade) gliomas in 104 surgical cases. This and
past studies have indicated a link between increased or more complete
removal of some types of tumors and longer life expectancy and quality
of life.

Use of iMRI, according to the article, was associated with improvement
in the median amount of tumor removal from 94.9 percent before iMRI to
a final of 99.6 percent post-surgery after iMRI. Complete resection was
possible in 65 percent of patients when iMRI was used compared to 34
percent without iMRI. All resection results were considered
statistically significant.

The results reinforce previously published evidence that IMRIS systems
with high-field iMRI-guided surgery are more effective in achieving
complete resection than conventional surgery using neuronavigation and
direct visualization alone.

This published evidence from leading neurosurgical hospitals using iMRI
showed that in over 40% of all cases, the surgeon chose to modify their
approach based on new information from intraoperative MR imaging that
would otherwise not have been available until after completing the
procedure. Furthermore, in over 55% of glioma tumor cases, additional
brain tumor was identified and resected after imaging. In addition,
these centers report significant improvements – about 30 percentage
points – in the portion of cases achieving total or complete tumor
resection with intraoperative MR compared to cases without it.

A VISIUS Surgical Theatre with high-field iMRI provides surgeons with
on-demand access to real-time data and diagnostic quality imaging
during the procedure from the OR table. Patient transport for imaging
is eliminated as the scanner uniquely moves to the patient on
ceiling-mounted rails. IMRIS also provides proprietary head fixation
devices, imaging coils, and OR tables for use in this unique and
multifunctional intraoperative environment.

“We applaud the authors for their careful analysis which once again
shows how intraoperative MR is an effective tool, particularly with the
diagnostic quality imaging only IMRIS can provide during surgeries
without moving the patient from the OR,” said IMRIS CEO and President
Jay D. Miller. “We continue to look at ways to improve iMR and
facilitate workflow through new protocols and accessories like coils,
headrests and head fixation devices to enhance patient outcomes for a
growing number of neurosurgical applications.”

The Neurosurgery article “Use of High-Field Intraoperative Magnetic
Resonance Imaging to Enhance the Extent of Resection of Enhancing and
Nonenhancing Gliomas” is available free on the publication website: http://journals.lww.com/neurosurgery/Fulltext/2014/04000.

About IMRIS

IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image
guided therapy solutions through its VISIUS Surgical Theatre – a
revolutionary, multifunctional surgical environment that provides
unmatched intraoperative vision to clinicians to assist in decision
making and enhance precision in treatment. The multi-room suites
incorporate diagnostic quality high-field MR, CT and angio modalities
accessed effortlessly in the operating room setting. VISIUS Surgical
Theatres serve the neurosurgical, spinal, cardiovascular and
cerebrovascular markets and have been selected by 57 leading medical
institutions around the world.




SOURCE IMRIS Inc.


Source: PR Newswire



comments powered by Disqus